Skip Navigation
Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español | E-mail UpdatesE-mail Updates
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Search Results to Slide Tray Search:

"reliability"

Slides: 1–12 of 16
Add to tray Remove from tray

Clinical Questions Addressed by the CER (2 of 2)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | assessment instrument | reliability | validity | responsiveness
Add to tray Remove from tray

Evaluating JIA Assessment Instruments (1 of 3)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: active joint count | anti-rheumatic | antirheumatic | assessment | biologic DMARD | CHAQ | CHQ | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | parent global assessment of well-being | PedsQL | PedsQL-RM | physician global assessment | reliability | responsiveness | rheumatic | TNF-alpha blockers | validity | juvenile idiopathic arthritis
Add to tray Remove from tray

Evaluating JIA Assessment Instruments (3 of 3)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: anti-rheumatic | antirheumatic | assessment | biologic DMARD | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | reliability | responsiveness | rheumatic | TNF-alpha blockers | validity | juvenile idiopathic arthritis
Add to tray Remove from tray

Results From Evaluation of JIA Assessment Instruments (1 of 2)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: active joint count | AJC | anti-rheumatic | antirheumatic | assessment | biologic DMARD | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | parent assessment of well-being | PGA | PGW | physician global assessment | reliability | responsiveness | rheumatic | TNF-alpha blockers | validity | juvenile idiopathic arthritis
Add to tray Remove from tray

Results From Evaluation of JIA Assessment Instruments (2 of 2)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | assessment | validity | reliability | responsiveness | active joint count | physician global assessment | parent assessment of well-being | AJC | PGA | PGW | CHAQ | CHq | PedsQL | PedsQl-RM
Add to tray Remove from tray

Evaluating JIA Assessment Instruments: Conclusions (1 of 2)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | assessment | validity | reliability | responsiveness | CHAQ
Add to tray Remove from tray

Evaluating JIA Assessment Instruments: Conclusions (2 of 2)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | assessment | validity | reliability | responsiveness
Add to tray Remove from tray

Conclusions About Benefits and Adverse Effects of DMARDs (1 of 2)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: active joint count | AJC | anti-rheumatic | antirheumatic | assessment | biologic DMARD | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | parent assessment of well-being | PGA | PGW | physician global assessment | reliability | responsiveness | rheumatic | TNF-alpha blockers | validity | juvenile idiopathic arthritis
Further Guidance: Principles for Scoring. Be explicit about how the evidence grade will be determined. A point system for combining ratings of the domains. A qualitative consideration of the domains. Carefully document procedures. Keep records of procedures and results for each review so that they may contribute to the overall expertise of the Evidence-based Practice Center and the science of grading evidence.
Add to tray Remove from tray

Further Guidance: Principles for Scoring

Presentation: Grading Strength of Evidence
Keywords: Evidence-based Practice Center | transparency | strength of evidence | body of evidence | GRADE | comparative effectiveness review
Add to tray Remove from tray

Clinical Questions Addressed in the CER: Screening and Monitoring

Presentation: Management of Chronic Kidney Disease Stages 1–3
Keywords: adverse effects | adverse effects | benefits | clinical outcomes | harms | monitoring | screening
Add to tray Remove from tray

Results of the Systematic Review: Evaluation of UI Treatment-Monitoring Methods (1 of 2)

Presentation: Non-surgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness
Keywords: urinary incontinence | stress incontinence | urge incontinence | urgency incontinence | mixed incontinence | symptom bother | screening | quality of life | patient satisfaction | validity | reliability
Add to tray Remove from tray

Outcome Measurement Properties

Presentation: Outcome Definition and Measurement in Observational Comparative Effectiveness Research
Keywords: outcome measurement properties | reliability | validity | variability
Pages: [1] 2 Next
 
 
 
 
www.ahrq.gov AHRQ Home | Questions? | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal

Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364